B E Immuno Sciences Private Limited - Due diligence report

A 360° intelligence report on B E Immuno Sciences Private Limited: trust score, financial health, credit view, compliance, directors, growth…

1999-05-24 Hyderabad, Telangana Active Unlisted Active Compliant
Share
Connect MCP
BE B E Immuno Sciences Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

B E Immuno Sciences Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
83/100
Trust Score
Low Risk

B E Immuno Sciences Private Limited is assessed as Low Risk with a Trust Score of 83/100. B E Immuno Sciences Private Limited is an active private limited indian non-government company incorporated in 1999, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 03 Aug 2026 from the latest processed filings. B E Immuno Sciences Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
83/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Moderate gearing (D/E 38%).

Charges position: 1 open (185.00 cr) · 1 satisfied (18.92 Lakh).

Banking relationships (from registered charges)
LenderChargesAmount
Others1 48.0 cr
Panjab National Bank1 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SRIDHAR PUSAPATI RAJU 01234567 Director 01/04/2018 6 yrs Approved
MAHIMA DATLA 01234567 Director 01/04/2018 6 yrs Approved
MANTENA PURNIMA 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2021 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 45 · Distress 65
Growth signals & trust indicators
Asset base grew 1.42 - capacity expansion.
Operating for 27+ years.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Outside liabilities up 2.1x in a year.
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence84/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment61/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 185.00 cr already registered.
  • Compliance record supports lending.
Investor view60/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 10 events
10 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
26 Jun 2024
Charge created
Others - 185.00 cr
28 Aug 2014
Charge satisfied
Panjab National Bank
12 Apr 2013
Director appointed
MANTENA PURNIMA (Additional Director)
20 Mar 2013
Director ceased
VIJAYKUMAR DATLA
25 Nov 2011
Charge created
Panjab National Bank - 18.92 Lakh
24 May 1999
Incorporated
Registered with Roc Hyderabad
Director appointed
SRIDHAR PUSAPATI RAJU (Director)
Director appointed
MAHIMA DATLA (Director)
10

Key Observations

Auto-generated from the data above
Revenue declined 24% over the last 4 financial year(s).
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2021 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Seavens Pharmaceutical Private Limited U51909RJ2020PTC067968 Jaipur, Rajasthan, India
Inverse Pharmaceuticals Private Limited U24230UP2021PTC142858 Kanpur, Uttar Pradesh, India
Fibrica Healthcare Private Limited U24299GJ2016PTC093172 Ahmedabad, Gujarat, India
Noble Remedies(India)Pvt Ltd U24231HR1978PTC009216 Na, Haryana, India
Celui Pharma Private Limited U51909GJ2017PTC095044 Ahmedabad, Gujarat, India
Delmax Pharmaceuticals Private Limited U24100MH2019PTC326834 Aurangabad, Maharashtra, India
Rmanirex Pharma Private Limited U51909TG2020PTC142591 Hyderabad, Telangana, India
Dymexa Biotech Private Limited U85100AS2020PTC020098 Guwahati, Assam, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify B E Immuno Sciences Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of B E Immuno Sciences Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 45/100, margin trends, ownership structure and peer set for B E Immuno Sciences Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 83/100, distress signals and MSME payment-delay disclosures - know whether B E Immuno Sciences Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for B E Immuno Sciences Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is B E Immuno Sciences Private Limited an active company?

B E Immuno Sciences Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is B E Immuno Sciences Private Limited financially healthy?

B E Immuno Sciences Private Limited has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.

Should I do business with B E Immuno Sciences Private Limited?

Its overall Trust Score is 83/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls B E Immuno Sciences Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does B E Immuno Sciences Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is B E Immuno Sciences Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to B E Immuno Sciences Private Limited?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.